American Society of Hematology Annual Meeting & Exposition (ASH) | Conference

Serum Ferritin Yields Response With Momelotinib in Myelofibrosis
January 08, 2022

At 24 weeks, patients with myelofibrosis transfused with serum ferritin and receiving momelotinib experienced a treatment response.

Storing Red Blood Cells in a Hypoxic State vs Normoxia Could Lower Adhesion
January 07, 2022

Investigators believe that storing red blood cells in a hypoxic state could reduce the development of vaso-occlusion flowing transfusion.

Outcomes With the CD3/CD123 Bispecific Antibody APVO436 Appear Unaffected by CRS and Interventional Steroids in AML/MDS
January 05, 2022

CD123- and CD3-engaging bispecific antibody, APVO436, caused cytokine release syndrome that could be managed through the use of steroids in patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.

aGVHD Incidence Following HSCT May be Reduced Following Treatment With Itolizumab
January 03, 2022

Patients receiving hematopoietic stem cell transplantation appeared to have improved outcomes and a decreased incidence of acute graft-versus-host disease after being treated with itolizumab.

Amphiregulin Appears to be a Promising Predictive Marker for Mortality in Acute Graft-Versus-Host Disease
December 29, 2021

Patients who have been diagnosed with acute graft-versus-host disease with high levels of amphiregulin could be at a higher risk for early mortality.

Thrombosis Risk May Be Identified With IPSS Score and JAK2 Status for Patients With Primary Myelofibrosis
December 27, 2021

Using the International Prognostic Scoring System (IPSS) score and JAK2 mutation status, thrombosis risk could potentially be identified for patients with primary myelofibrosis.

Steven Devine, MD, Discusses Exciting Abstracts From ASH 2021
December 17, 2021

Steven Devine, MD, spoke about which abstracts he found most interesting at ASH 2021.

Quality of Life Improved With Second-Line Liso-Cel in R/R LBCL
December 15, 2021

Second-line treatment of lisocabtagene maraleucel demonstrated improved quality of life in patients with large B-cell lymphoma.

Cytopenic Myelofibrosis Benefits from Full-Dose Pacritinib Vs Ruxolitinib
December 14, 2021

Data from a retrospective head-to-head analysis of pacritinib vs ruxolitinib showed that the former was more favorable in terms of symptom response for patients with myelofibrosis and thrombocytopenia.

Pacritinib Produced Comparable Safety Profile to Best Available Therapy for Cytopenic Myelofibrosis, Severe Thrombocytopenia
December 14, 2021

Patients with cytopenic myelofibrosis produced a tolerable safety profile when receiving treatment with pacritinib.